Helicobacter Pylori Eradication in Functional Dyspepsia

• Status: Completed
• Trial end date: 2019-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to study benefit of eradicating Helicobacter Pylori in patients with functional dyspepsia as compared to symptomatic treatment only. Helicobacter pylori positive patients with Functional Dyspepsia will be divided into two study groups, one will receive Helicobacter pylori eradication therapy and other will receive symptomatic treatment. Symptom relief based on Likert scale will be compared in both groups.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sir Ganga Ram Hospital
• Treatments: Amoxicillin; Clarithromycin; Pantoprazole; Proton Pump Inhibitors; Z 338

Criteria

Inclusion Criteria:

• Age > 18 years

• Patients fulfilling the ROME-IV criteria of Functional Dyspepsia

• Signed informed consent.

Exclusion Criteria:

• Pregnant and lactating females

• Patients with predominant symptoms of heartburn or irritable bowel syndrome; alarm symptoms; history of peptic ulcer, upper gastrointestinal tract surgery, or biliary colic

• Previous treatment for eradication of H pylori.

• Known allergies to study medication or alcohol or drug abuse.

• Use of antibiotics or bismuth during the 4 weeks before enrolment, proton pump inhibitors during the 2 weeks before enrolment, or treatment with histamine-2 receptor blockers in the week before enrolment will not be permitted.

• Patients unable to answer the study questionnaires.

• Patients unwilling or unable to provide consent.

• Patient on HIV/AIDS medications, blood thinners, clopidogrel, cyclosporine, digoxin, iron supplements, fluconazole or ketoconazole, probenecid, rifabutin, sildenafil, tacrolimus, theophylline, sulfa drugs, cholesterol-lowering medicines, heart rhythm medications, sedatives, seizure medications, or tetracycline antibiotics.